Oh, nonsense. This is just the 105 calls washing out. Watch this bounce above that level at the close ...in any event, this will be back to 107.50 on Monday.
The stock is under accumulation.
Appreciate your frankness. PREVAIL, the recently completed trial on which the pre-chemo approval was based, was Xtandi vs placebo. You could extrapolate from this that Xtandi was superior to Zytiga, however the trials were not exctly comparable, I believe, since the Zytiga vs placebo trial was stopped before an overall survival benefit was defined. TERRAIN is a smaller scale European trial of Xtandi vs Zytiga in metastatic pre-chemo patients. It parallels the STRIVE trial, which is being conducted in the US and has enrolled both metastatic and non-metastatic pre-chemo patients and also compare Xtandi vs Zytiga. Neither of these is as significant, in my opinion, as the much larger scale PROSPER trial, which compares Xtandi vs placebo in non-metastatic patients who are progessing (i.e. PSA rising) despite androgen deprivation thereapy.
You obviously recognize the well-known axiom that you make money by trading AGAINST Cramer's recommendations. His statement that GILD ismore risky than ACAD or ISIS is absurd on the face of it. I don't know what kind of speed he's on, but I'd say he's overdue for a long vacation.
Interesting question. I'll bet a lot more people are using GTC lowball buy orders.
Well, I think that they'll paint the tape with some minus trades in the morning and try to convince you otherwise. They seemed very determined to keep it from going green today. However, this is certainly headed above 100 pretty soon.
Johny, I'd just point out that the folks who are short those 41,000 shares of DNDN, even assuming that they have stop losses at a distant 1.50, have about $4,000 at risk.
Now we've traded 2,000,000 shares and made back 3.60 of that 4 buck drop at the open. I think perhaps we will do another half million in the final hour and a quarter.
I had buy orders in at 95.82 and below, which didn't quite fill. "I have seen the marketmakers selling each to each. I do not think they will sell to me."
Note that early this morning, this had traded about 1,000,000 shares and was down four bucks. Let's see where it is when it has traded 2,000,000 shares. If the daytraders would stop putting in stops, this would quickly turn green. A good general rule in these situations is to put in buy orders where others have stops.
I thought 93.75 was a good point to add shares. Looks like they will play it here for a while, letting it drift up toward 96.50, then dropping it back to take out the stops of the retail daytraders and pick up more shares. Important to note that, as would be expected after yesterday's strong run, the biotech indices and ETF's are down today. (IBB -1.25%, Amex Biotech Index -1.64%, etc.) Anything in the category that is up or close to even is an anomaly. The fact is, at the point where the resident Dendreonites were urging all to "SHORT THIS POS!" this morning, you could have shorted the bellwethers of the sector (GILD, BIIB, CELG, AMGN, etc.) and made some money. Or, you could have just shorted the indices. The one move which would have cost you dearly would have been to short MDVN.
Short itright here at 93.96 ...if you have any money left to lose. I just added @ 93.75. This will bounce as the institutions, having sold to shake out retail investors, buy those shares back.
Well, PCYC from 2 to125 is the kind of investment we all dream about. After the fact it seems so simple: Ibrutinib is a game-changing drug, so buy and hold on. But along the way, there are many diversions, false alarms and feints which cause many to lose faith. I feel the same way about Xtandi: Just buy it and keep it. When it weakens, buy more. Continued good luck to you.
I added shares AH. But I wouldn't be surprised if they let it falter at the open to attract some shorts and then drive it higher.
Hey, this time his post only contains 2 outright lies. Still hasn't broken his old record of 6 lies in two sentences.